386 related articles for article (PubMed ID: 29636383)
1. Colesevelam attenuates cholestatic liver and bile duct injury in
Fuchs CD; Paumgartner G; Mlitz V; Kunczer V; Halilbasic E; Leditznig N; Wahlström A; Ståhlman M; Thüringer A; Kashofer K; Stojakovic T; Marschall HU; Trauner M
Gut; 2018 Sep; 67(9):1683-1691. PubMed ID: 29636383
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
3. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
[TBL] [Abstract][Full Text] [Related]
4. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
[TBL] [Abstract][Full Text] [Related]
5. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
[TBL] [Abstract][Full Text] [Related]
6. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
Miethke AG; Zhang W; Simmons J; Taylor AE; Shi T; Shanmukhappa SK; Karns R; White S; Jegga AG; Lages CS; Nkinin S; Keller BT; Setchell KD
Hepatology; 2016 Feb; 63(2):512-23. PubMed ID: 26172874
[TBL] [Abstract][Full Text] [Related]
8. Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development.
Zhou E; Hoeke G; Li Z; Eibergen AC; Schonk AW; Koehorst M; Boverhof R; Havinga R; Kuipers F; Coskun T; Boon MR; Groen AK; Rensen PCN; Berbée JFP; Wang Y
Cardiovasc Res; 2020 Aug; 116(10):1710-1720. PubMed ID: 31589318
[TBL] [Abstract][Full Text] [Related]
9. Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass.
Jonsson I; Bojsen-Møller KN; Kristiansen VB; Veedfald S; Wewer Albrechtsen NJ; Clausen TR; Kuhre RE; Rehfeld JF; Holst JJ; Madsbad S; Svane MS
Front Endocrinol (Lausanne); 2021; 12():681116. PubMed ID: 34084153
[TBL] [Abstract][Full Text] [Related]
10. Metabolic preconditioning protects BSEP/ABCB11
Fuchs CD; Paumgartner G; Wahlström A; Schwabl P; Reiberger T; Leditznig N; Stojakovic T; Rohr-Udilova N; Chiba P; Marschall HU; Trauner M
J Hepatol; 2017 Jan; 66(1):95-101. PubMed ID: 27593105
[TBL] [Abstract][Full Text] [Related]
11. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
Liu Y; Chen K; Li F; Gu Z; Liu Q; He L; Shao T; Song Q; Zhu F; Zhang L; Jiang M; Zhou Y; Barve S; Zhang X; McClain CJ; Feng W
Hepatology; 2020 Jun; 71(6):2050-2066. PubMed ID: 31571251
[TBL] [Abstract][Full Text] [Related]
12. Geniposide suppresses liver injury in a mouse model of DDC-induced sclerosing cholangitis.
Wen M; Liu Y; Chen R; He P; Wu F; Li R; Lin Y
Phytother Res; 2021 Jul; 35(7):3799-3811. PubMed ID: 33763888
[TBL] [Abstract][Full Text] [Related]
13. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
14. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
[TBL] [Abstract][Full Text] [Related]
15. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice.
Potthoff MJ; Potts A; He T; Duarte JA; Taussig R; Mangelsdorf DJ; Kliewer SA; Burgess SC
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(4):G371-80. PubMed ID: 23257920
[TBL] [Abstract][Full Text] [Related]
16. Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
Li J; Zhu X; Zhang M; Zhang Y; Ye S; Leng Y; Yang T; Kong L; Zhang H
J Hepatol; 2021 Aug; 75(2):400-413. PubMed ID: 33746084
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells.
Trabelsi MS; Daoudi M; Prawitt J; Ducastel S; Touche V; Sayin SI; Perino A; Brighton CA; Sebti Y; Kluza J; Briand O; Dehondt H; Vallez E; Dorchies E; Baud G; Spinelli V; Hennuyer N; Caron S; Bantubungi K; Caiazzo R; Reimann F; Marchetti P; Lefebvre P; Bäckhed F; Gribble FM; Schoonjans K; Pattou F; Tailleux A; Staels B; Lestavel S
Nat Commun; 2015 Jul; 6():7629. PubMed ID: 26134028
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
19. Wnt/β-Catenin Signaling Plays a Protective Role in the Mdr2 Knockout Murine Model of Cholestatic Liver Disease.
Pradhan-Sundd T; Kosar K; Saggi H; Zhang R; Vats R; Cornuet P; Green S; Singh S; Zeng G; Sundd P; Nejak-Bowen K
Hepatology; 2020 May; 71(5):1732-1749. PubMed ID: 31489648
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of berberine in attenuating cholestatic liver injury: insights from a PSC mouse model.
Wang Y; Zhao D; Su L; Tai YL; Way GW; Zeng J; Yan Q; Xu Y; Wang X; Gurley EC; Zhou XQ; Liu J; Liu J; Chen W; Hylemon PB; Zhou H
Cell Biosci; 2024 Jan; 14(1):14. PubMed ID: 38273376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
